NASDAQ$TCRX
Tscan Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
TScan Therapeutics reported financial results and highlighted recent company progress.
TScan Therapeutics reported a net loss of $15.8 million for the third quarter of 2021, with research and development expenses at $14.2 million and general and administrative expenses at $4.0 million. The company's cash and cash equivalents totaled $182.3 million as of September 30, 2021, expected to fund operations into 2024. They are advancing their TCR-T therapy candidates, including IND submissions expected for TSC-100 and TSC-101 in Q4 2021.
- Advanced lead TCR-T therapy candidate for TSC-200 program into IND-enabling activities.
- Discovered a novel HLA-C*07:02-restricted epitope encoded by the MAGE-A1 gene and launched a new program, TSC-204.
- Expanded management team with appointments of Zoran Zdraveski as Chief Legal Officer and Heather Savelle as VP, Investor Relations.
- Completed initial public offering in July 2021, raising $100 million in gross proceeds.
Headline financials
Revenue & EPS history
Tscan Therapeutics · Revenue · Quarterly
$2.41M
Revenue by segment
Tscan Therapeutics · $3.89M total across 1 segment · Q3 2023
- Collaboration & License$3.89M—100.0%
Forward guidance
TScan Therapeutics anticipates key milestones for its liquid and solid tumor programs, including IND submissions and clinical trial initiations, while continuing research into infectious disease programs.
Tailwinds
- Present two posters related to TSC-100 and TSC-101 at the upcoming ASH Annual Meeting and Exposition.
- IND-enabling studies and the submission of IND applications to the FDA are planned for TSC-100 and TSC-101 during the fourth quarter 2021.
- Following the IND submissions and pending acceptance by the FDA, clinical trials for TSC-100 and TSC-101 are expected to begin in the first half of 2022 with preliminary data expected in the second half of 2022.
- TScan plans to present preclinical data of the TSC-2xx series during the first half of 2022.
- TScan plans to progress IND-enabling studies for the TSC-2xx series and submit IND applications during the second half of 2022, including for TSC-200 for HPV, during the second half of 2022.
Headwinds
- Uncertainties regarding the timing of preclinical studies and clinical trials.
- Dependence on regulatory requirements and ability to obtain and maintain intellectual property protection.
- Potential challenges in attracting or retaining key personnel.
- Risks associated with establishing and maintaining development partnerships and collaborations.
- Potential impact of the COVID-19 pandemic on TScan’s business and operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+1.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-5.7%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+32.4%
Q1 2023
Best reaction
-18.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -3.3% | -18.9% | |
| Q4 2025 | +4.9% | +19.8% | -2.4% | |
| Q3 2025 | +0.8% | -20.5% | -17.2% | |
| Q2 2025 | +3.1% | +11.8% | +14.9% | |
| Q1 2025 | -4.6% | +0.8% | +18.3% | |
| Q4 2024 | +2.6% | +7.7% | -7.1% | |
| Q3 2024 | -7.9% | -22.6% | -47.0% | |
| Q2 2024 | -1.0% | -3.0% | -3.9% | |
| Q1 2024 | +16.3% | +16.2% | +14.9% | |
| Q4 2023 | +1.6% | -6.7% | +0.9% | |
| Q3 2023 | +3.0% | +14.9% | +50.8% | |
| Q2 2023 | -4.2% | -2.3% | +12.1% | |
| Q1 2023 | +32.4% | +18.5% | -14.4% | |
| Q4 2022 | -8.5% | -23.0% | -33.3% | |
| Q3 2022 | -0.4% | +3.9% | -20.6% | |
| Q2 2022 | -10.8% | -18.8% | -20.5% | |
| Q1 2022 | +10.6% | +38.3% | +80.0% | |
| Q4 2021 | +7.8% | -1.6% | -37.8% | |
| Q3 2021 | +2.2% | -4.4% | -28.0% | |
| Q2 2021 | -18.2% | -21.7% | -53.7% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro